论文部分内容阅读
目的:探讨顺铂联合氟尿嘧啶化疗对食管癌患者血清癌胚抗原(CEA)及角蛋白19片段(Cyfa21-1)浓度的影响及其临床疗效。方法:选择我院收治的食管癌患者60例,随机分为实验组和对照组,每组30例。对照组患者给予氟尿嘧啶,实验组患者在对照组的基础上联合使用顺铂。比较治疗前后两组患者血清CEA及Cyfa21-1浓度的变化,应用KPS评分表评价两组患者治疗前后的生活质量,并对比分析两组患者治疗后的临床疗效及不良反应。结果:与治疗前相比,两组患者血清CEA及Cyfa21-1浓度均较低,KPS评分较高(P<0.05);与对照组相比,实验组患者血清CEA及Cyfa21-1浓度较低,KPS评分较高(P<0.05);与对照组相比,实验组患者临床有效率较高,不良反应发生率较低,差异具有统计学意义(P<0.05)。结论:顺铂联合氟尿嘧啶能较单用氟尿嘧啶有效改善食管癌患者的生活质量,提高临床疗效。
Objective: To investigate the effect of cisplatin plus fluorouracil chemotherapy on serum CEA and Cyfa21-1 in patients with esophageal cancer and its clinical efficacy. Methods: Sixty patients with esophageal cancer admitted to our hospital were randomly divided into experimental group and control group, with 30 cases in each group. Patients in the control group were given fluorouracil, and patients in the experimental group were given cisplatin on the basis of the control group. The changes of serum CEA and Cyfa21-1 concentrations in two groups before and after treatment were compared. The KPS score was used to evaluate the quality of life before and after treatment. The clinical efficacy and adverse reactions were compared between the two groups after treatment. Results: Compared with those before treatment, the concentrations of serum CEA and Cyfa21-1 in both groups were lower and the KPS scores were higher (P <0.05). Compared with the control group, serum CEA and Cyfa21-1 concentrations in the experimental group were lower (P <0.05). Compared with the control group, the clinical efficacy rate and the incidence of adverse reactions in the experimental group were significantly lower (P <0.05). Conclusion: Cisplatin plus fluorouracil can effectively improve the quality of life of patients with esophageal cancer and improve the clinical efficacy compared with fluorouracil alone.